“`html
Heart Failure Treatment Advances: SGLT2 Inhibitors, Finerenone & ARNI Therapies
The landscape of heart failure treatment is undergoing a notable transformation, particularly for individuals diagnosed with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Recent clinical trials have demonstrated the efficacy of several novel pharmacological interventions, offering renewed hope for improved outcomes. This article delves into the latest advancements, focusing on sodium glucose co-transporter-2 inhibitors (SGLT2i), the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone, and the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, and how they are reshaping the management of these complex conditions. As of October 7,2025,these therapies represent a cornerstone of modern heart failure care.
Understanding heart Failure with Mid-Range and Preserved Ejection Fraction
Traditionally,heart failure classification relied heavily on ejection fraction (EF),the percentage of blood the left ventricle pumps out with each contraction. however,recognizing the distinct clinical profiles within the spectrum,guidelines now categorize heart failure into three main groups: heart failure with reduced ejection fraction (HFrEF),HFmrEF (EF 41-49%),and HFpEF (EF ≥50%). HFmrEF and HFpEF, historically considered more challenging to treat, now benefit from targeted therapies. The prevalence of HFpEF is increasing,driven by an aging population and rising rates of comorbidities like obesity,diabetes,and hypertension – conditions that were estimated to effect over 133 million adults in the US in 2023,according to the CDC. This shift in demographics underscores the urgent need for effective treatment strategies.
The Role of SGLT2 Inhibitors in Heart Failure
sodium glucose co-transporter-2 inhibitors (SGLT2i), initially developed for type 2 diabetes management, have surprisingly emerged as powerful tools in heart failure therapy. These medications – including empagliflozin, dapagliflozin, and canagliflozin – work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. However, their benefits extend far beyond glycemic control. Clinical trials, such as EMPEROR-Preserved and DELIVER, have convincingly shown that SGLT2i reduce hospitalization for heart failure and cardiovascular death in patients with HFmrEF and HFpEF, irrespective of diabetes status. The mechanism isn’t fully understood, but itS believed to involve improvements in cardiac energetics, reduced inflammation, and decreased arterial stiffness.
Did You Know? SGLT2 inhibitors have demonstrated a consistent benefit across diverse patient populations in heart failure trials, including those with and without diabetes, suggesting a disease-modifying effect independent of glucose control.
Finerenone: A Novel Approach to Mineralocorticoid Receptor Antagonism
Mineralocorticoid receptor antagonists (MRAs) have long been used in heart failure management,but conventional MRAs like spironolactone can be limited by side effects such as hyperkalemia (high potassium levels) and gynecomastia (breast enlargement in men). Finerenone,a non-steroidal MRA,offers a more selective approach,minimizing these adverse effects. The FIDELIO-DKD trial, and afterward the FINEARTS-HF trial, demonstrated that finerenone considerably reduced the risk of cardiovascular events and kidney disease progression in patients with type 2 diabetes and chronic kidney disease, and importantly, showed benefit in HFmrEF/hfpef.
Related reading